LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 63

Search options

  1. Article ; Online: Is global BCG vaccination-induced trained immunity relevant to the progression of SARS-CoV-2 pandemic?

    Gursel, Mayda / Gursel, Ihsan

    Allergy

    2020  Volume 75, Issue 7, Page(s) 1815–1819

    MeSH term(s) BCG Vaccine/immunology ; Betacoronavirus/immunology ; COVID-19 ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Coronavirus Infections/transmission ; Coronavirus Infections/virology ; Humans ; Immunogenicity, Vaccine ; Immunologic Memory ; Models, Statistical ; Pandemics ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Pneumonia, Viral/transmission ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Vaccination ; Vaccines, Attenuated/immunology
    Chemical Substances BCG Vaccine ; Vaccines, Attenuated
    Keywords covid19
    Language English
    Publishing date 2020-06-08
    Publishing country Denmark
    Document type Letter
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.14345
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?

    Gursel, Mayda / Gursel, Ihsan

    Medical Hypotheses

    Abstract: The lower than expected number of SARS-CoV-2 cases in countries with fragile health systems is puzzling Herein, we hypothesize that BCG vaccination policies adopted by different countries might influence the SARS-CoV-2 transmission patterns and/or COVID- ... ...

    Abstract The lower than expected number of SARS-CoV-2 cases in countries with fragile health systems is puzzling Herein, we hypothesize that BCG vaccination policies adopted by different countries might influence the SARS-CoV-2 transmission patterns and/or COVID-19 associated morbidity and mortality through the vaccine’s capacity to confer heterologous protection We also postulate that until a specific vaccine is developed, SARS-CoV-2 vulnerable populations could be immunized with BCG vaccines to attain heterologous nonspecific protection from the new coronavirus
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #34968
    Database COVID19

    Kategorien

  3. Article ; Online: WITHDRAWN

    Gursel, Mayda / Gursel, Ihsan

    Medical Hypotheses

    Is global BCG vaccination coverage relevant to the progression of SARS-CoV-2 pandemic?

    2020  , Page(s) 109707

    Keywords General Medicine ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 193145-3
    ISSN 1532-2777 ; 0306-9877
    ISSN (online) 1532-2777
    ISSN 0306-9877
    DOI 10.1016/j.mehy.2020.109707
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  4. Article ; Online: Is global BCG vaccination‐induced trained immunity relevant to the progression of SARS‐CoV‐2 pandemic?

    Gursel, Mayda / Gursel, Ihsan

    Allergy

    2020  Volume 75, Issue 7, Page(s) 1815–1819

    Keywords Immunology ; Immunology and Allergy ; covid19
    Language English
    Publisher Wiley
    Publishing country us
    Document type Article ; Online
    ZDB-ID 391933-x
    ISSN 1398-9995 ; 0105-4538
    ISSN (online) 1398-9995
    ISSN 0105-4538
    DOI 10.1111/all.14345
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  5. Article ; Online: DOCK8 deficiency with hypereosinophilia and the syndrome of inappropriate antidiuretic hormone secretion during herpes infection.

    Yeşil, Ayşe Mete / Kayaoğlu, Başak / Gül, Ersin / Gönç, Nazlı / Özön, Alev / Tezcan, İlhan / Gürsel, Mayda / Çağdaş, Deniz

    The Turkish journal of pediatrics

    2023  Volume 65, Issue 3, Page(s) 536–541

    Abstract: Background: Hyperimmunoglobulin E syndrome (HIES) due to dedicator of cytokinesis8 (DOCK8) deficiency may present in infancy and childhood with different clinical features involving recurrent infections, allergic dysregulation, and autoimmunity.: Case! ...

    Abstract Background: Hyperimmunoglobulin E syndrome (HIES) due to dedicator of cytokinesis8 (DOCK8) deficiency may present in infancy and childhood with different clinical features involving recurrent infections, allergic dysregulation, and autoimmunity.
    Case: In this report, we describe a patient who first presented with severe hypereosinophilia and went on to develop the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in the context of a severe herpes infection. Investigation revealed the presence of underlying DOCK8 deficiency presenting with atypical clinical features.
    Conclusions: Distinct inflammatory features associated with infections may be seen in the course of primary immunodeficiency diseases, and early functional and molecular genetic tests will aid the proper management.
    MeSH term(s) Child ; Humans ; Eosinophilia ; Guanine Nucleotide Exchange Factors/genetics ; Hypersensitivity/complications ; Inappropriate ADH Syndrome/diagnosis ; Inappropriate ADH Syndrome/genetics ; Inappropriate ADH Syndrome/complications ; Job Syndrome/complications ; Job Syndrome/diagnosis ; Job Syndrome/genetics ; Vasopressins ; Infant
    Chemical Substances DOCK8 protein, human ; Guanine Nucleotide Exchange Factors ; Vasopressins (11000-17-2)
    Language English
    Publishing date 2023-06-15
    Publishing country Turkey
    Document type Case Reports ; Research Support, Non-U.S. Gov't
    ZDB-ID 123487-0
    ISSN 2791-6421 ; 0041-4301
    ISSN (online) 2791-6421
    ISSN 0041-4301
    DOI 10.24953/turkjped.2020.1934
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Immunogenicity and Protective Capacity of CpG ODN Adjuvanted Alum Adsorbed Bivalent Meningococcal Outer Membrane Vesicle Vaccine.

    Canavar Yildirim, Tugce / Ozsurekci, Yasemin / Yildirim, Muzaffer / Evcili, Irem / Yazar, Volkan / Aykac, Kubra / Guler, Ulku / Salih, Bekir / Gursel, Mayda / Gursel, Ihsan

    International immunology

    2024  

    Abstract: Invasive meningococcal disease (IMD) is caused by Neisseria meningitidis, with the main serogroups responsible for the disease being A, B, C, W, X, and Y. To date, several vaccines targeting N.meningitidis have been developed albeit with a short-lived ... ...

    Abstract Invasive meningococcal disease (IMD) is caused by Neisseria meningitidis, with the main serogroups responsible for the disease being A, B, C, W, X, and Y. To date, several vaccines targeting N.meningitidis have been developed albeit with a short-lived protection. Given that MenW and MenB are the most common causes of IMD in Europe, Turkey, and Middle East, we aimed to develop an outer membrane vesicle (OMV) based bivalent vaccine as the heterologous antigen source. Herein, we compared the immunogenicity, and breadth of serum bactericidal assays (SBA) based protective coverage of OMV vaccine to X serotype with existing commercial meningococcal conjugate and polysaccharide (PS) vaccines in a murine model. BALB/c mice were immunized with preclinical batches of the W+B OMV vaccine, either adjuvanted with Alum, CpG ODN or their combinations and compared with a MenACYW conjugate vaccine (NimenrixTM, Pfizer) and a MenB OMV-based vaccine (Bexsero®, GSK), The immune responses were assessed through ELISA and SBA. Antibody responses and SBA titers were significantly higher in the W+B OMV vaccine when adjuvanted with Alum or CpG ODN, as compared to the control groups. Moreover, the SBA titers were not only significantly higher than those achieved with available conjugated ACYW vaccines but also on par with the 4CMenB vaccines. In conclusion, the W+B OMV vaccine demonstrated the capacity to elicit robust antibody responses, surpassing or matching the levels induced by licensed meningococcal vaccines. Consequently, the W+B OMV vaccine could potentially serve as a viable alternative or supplement to existing meningococcal vaccines.
    Language English
    Publishing date 2024-03-27
    Publishing country England
    Document type Journal Article
    ZDB-ID 1013745-2
    ISSN 1460-2377 ; 0953-8178
    ISSN (online) 1460-2377
    ISSN 0953-8178
    DOI 10.1093/intimm/dxae016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a partial STING agonist, competes for human STING activation.

    Temizoz, Burcu / Shibahara, Takayuki / Hioki, Kou / Hayashi, Tomoya / Kobiyama, Kouji / Lee, Michelle Sue Jann / Surucu, Naz / Sag, Erdal / Kumanogoh, Atsushi / Yamamoto, Masahiro / Gursel, Mayda / Ozen, Seza / Kuroda, Etsushi / Coban, Cevayir / Ishii, Ken J

    Frontiers in immunology

    2024  Volume 15, Page(s) 1353336

    Abstract: 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a mouse-selective stimulator of interferon gene (STING) agonist exerting STING-dependent anti-tumor activity. Although DMXAA cannot fully activate human STING, DMXAA reached phase III in lung cancer ... ...

    Abstract 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is a mouse-selective stimulator of interferon gene (STING) agonist exerting STING-dependent anti-tumor activity. Although DMXAA cannot fully activate human STING, DMXAA reached phase III in lung cancer clinical trials. How DMXAA is effective against human lung cancer is completely unknown. Here, we show that DMXAA is a partial STING agonist interfering with agonistic STING activation, which may explain its partial anti-tumor effect observed in humans, as STING was reported to be pro-tumorigenic for lung cancer cells with low antigenicity. Furthermore, we developed a DMXAA derivative-3-hydroxy-5-(4-hydroxybenzyl)-4-methyl-9
    MeSH term(s) Humans ; Mice ; Animals ; Membrane Proteins/metabolism ; Leukocytes, Mononuclear/metabolism ; Lung Neoplasms ; Lung/metabolism ; Xanthones
    Chemical Substances vadimezan (0829J8133H) ; Membrane Proteins ; Xanthones
    Language English
    Publishing date 2024-03-12
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1353336
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Development of CpG ODN Based Vaccine Adjuvant Formulations.

    Gursel, Mayda / Gursel, Ihsan

    Methods in molecular biology (Clifton, N.J.)

    2016  Volume 1404, Page(s) 289–298

    Abstract: Development of effective vaccine mediated immune responses relies on the use of vaccine adjuvants capable of enhancing and directing the adaptive immune response to the antigen. When used as vaccine adjuvants, type I interferon inducing agents can elicit ...

    Abstract Development of effective vaccine mediated immune responses relies on the use of vaccine adjuvants capable of enhancing and directing the adaptive immune response to the antigen. When used as vaccine adjuvants, type I interferon inducing agents can elicit potent effector/memory T cell responses and humoral immunity. Distinct sequences of single stranded synthetic oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanine oligodeoxynucleotide motifs (CpG ODN) can generate type I interferon production via a TLR9-MyD88-IRF7-mediated signaling pathway. Here, we describe two different methods of preparing CpG ODN-based vaccine adjuvant formulations that can induce a robust IFNα response from human peripheral blood mononuclear cells.
    MeSH term(s) Adjuvants, Immunologic/chemistry ; Adjuvants, Immunologic/pharmacology ; Amino Acid Sequence ; Base Sequence ; CpG Islands ; Drug Compounding/methods ; Drug Stability ; Electrophoresis, Agar Gel ; Humans ; Interferon-alpha/blood ; Leukocytes, Mononuclear/immunology ; Leukocytes, Mononuclear/metabolism ; Liposomes/chemistry ; Oligodeoxyribonucleotides/chemistry ; Oligodeoxyribonucleotides/immunology ; Peptides/chemistry
    Chemical Substances Adjuvants, Immunologic ; Interferon-alpha ; Liposomes ; Oligodeoxyribonucleotides ; Peptides
    Language English
    Publishing date 2016-04-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 1940-6029
    ISSN (online) 1940-6029
    DOI 10.1007/978-1-4939-3389-1_20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response

    Kocabas, Banu Bayyurt / Almacioglu, Kubra / Bulut, Esin Alpdundar / Gucluler, Gozde / Tincer, Gizem / Bayik, Defne / Gursel, Mayda / Gursel, Ihsan

    Journal of controlled release. 2020 Dec. 10, v. 328

    2020  

    Abstract: Nucleic acid-based pattern recognition receptor agonists are effective adjuvants and immunotherapeutic agents. Rather than single applications, ligand combinations could synergistically potentiate immune responses by elevating cytokine and chemokine ... ...

    Abstract Nucleic acid-based pattern recognition receptor agonists are effective adjuvants and immunotherapeutic agents. Rather than single applications, ligand combinations could synergistically potentiate immune responses by elevating cytokine and chemokine production via triggering multiple signaling pathways. However, short half-lives of such labile ligands due to nuclease attack and limited cellular uptake due to their structure significantly hamper their in vivo performances. More importantly, simultaneous delivery and activity presentation of protein antigen and nucleic acid ligands critically limit the clinical development of these constructs. In this work, we approached this problem by co-encapsulating a model antigen ovalbumin along with TLR9 and STING ligands within liposomes, a well-established drug delivery system that enables payload stability and enhanced cellular activity upon internalization. Moreover, by loading dual ligands we postulated to achieve heightened Th-1 immune response that would yield pronounced protective vaccine efficacy. We show that, pH-sensitive liposomes co-encapsulating CpG ODN and cGAMP induced synergistic innate immune response by elevating type I and type II interferon levels. Most importantly, this vaccine formulation led to ~70% regression of established melanoma tumor. pH-sensitive liposomal vaccine administration elevated IgG2c/IgG1 antibody ratio, indicative of augmented OVA-specific Th1-biased immunity. Importantly, while the frequency of tumor-specific IFN-γ producing CD8⁺ T-cells was significantly increased, the M2-type anti-inflammatory macrophage levels were decreased in the tumor bed. In conclusion, our strategy induces reversal of immunosuppressive tumor microenvironment, while enhancing effective anti-tumor immune-response. We propose that this could be coupled with standard therapies during combating tumor eradication.
    Keywords CD8-positive T-lymphocytes ; Toll-like receptor 9 ; adjuvants ; agonists ; antibodies ; antigens ; bites and stings ; chemokines ; drug delivery systems ; enzymes ; half life ; immune response ; immunoglobulin G ; immunosuppression ; immunotherapy ; innate immunity ; interferon-gamma ; ligands ; macrophages ; melanoma ; models ; nucleic acids ; oligodeoxyribonucleotides ; ovalbumin ; signal transduction ; vaccines
    Language English
    Dates of publication 2020-1210
    Size p. 587-595.
    Publishing place Elsevier B.V.
    Document type Article
    ZDB-ID 632533-6
    ISSN 1873-4995 ; 0168-3659
    ISSN (online) 1873-4995
    ISSN 0168-3659
    DOI 10.1016/j.jconrel.2020.09.040
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

To top